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Purpose: The impact of multileaf collimator (MLC) design and IMRT technique on plan quality and delivery
improvements for head-and-neck and meningioma patients is compared in a planning study.
Material and methods: Ten previously treated patients (5 head-and-neck, 5 meningioma) were re-planned for
step-and-shoot IMRT (ssIMRT), sliding window IMRT (dMLC) and VMAT using the MLCi2 without (−) and with (+)
interdigitation and the Agility-MLC attached to an Elekta 6MV linac. This results in nine plans per patient. Consistent
patient individual optimization parameters are used. Plans are generated using the research tool Hyperion V2.4
(equivalent to Elekta Monaco 3.2) with hard constraints for critical structures and objectives for target structures.
For VMAT plans, the improved segment shape optimization is used.
Critical structures are evaluated based on QUANTEC criteria. PTV coverage is compared by EUD, Dmean, homogeneity
and conformity. Additionally, MU/plan, treatment times and number of segments are evaluated.
Results: As constrained optimization is used, all plans fulfill the hard constraints. Doses to critical structures do not
differ more than 1Gy between the nine generated plans for each patient. Only larynx, parotids and eyes differ up to
1.5Gy (Dmean or Dmax) or 7 % (volume-constraint) due to (1) increased scatter, (2) not avoiding structures when using
the full range of gantry rotation and (3) improved leaf sequencing with advanced segment shape optimization for
VMAT plans. EUD, Dmean, homogeneity and conformity are improved using the Agility-MLC. However, PTV coverage is
more affected by technique. MU increase with the use of dMLC and VMAT, while the MU are reduced by using the
Agility-MLC. Fastest treatments are always achieved using Agility-MLC, especially in combination with VMAT.
Conclusion: Fastest treatments with the best PTV coverage are found for VMAT plans with Agility-MLC, achieving the
same sparing of healthy tissue compared to the other combinations of ssIMRT, dMLC and VMAT with either MLCi2−/+
or Agility.
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The major vendors of clinically used linear accelerators
(linacs) re-designed their multi-leaf-collimators (MLCs)
over time as importance of the leaf width, transmission,
maximum leaf speed and leaf positioning accuracy as
well as interdigitation capabilities was investigated in the
literature.
Burmeister et al. [1] and Wu et al. [2] demonstrated
that leaf width has only small impact on the plan quality* Correspondence: Steffi.Kantz@med.uni-muenchen.de
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article, unless otherwise stated.for large PTVs. Benefits of smaller leaf width and leaf
penumbra are predominantly encountered in cases of
small lesions and complex PTV or organs at risks (OAR)
[3–6]. Furthermore, smaller leaves may reduce radiation
to surrounding tissue by up to 5 % for the 70 and 50 %
isodose [4]. Bortfeld et al. [7] showed that the optimal
leaf width is 1.5–1.8 mm when neglecting transmission.
On the other hand, Topolniak et al. [5] showed trans-
mission to be one of the most important parameters
towards higher quality plans. As lower transmission
means lower dose to surrounding tissues, either less
dose to healthy tissue or higher modulation degrees
become feasible.is distributed under the terms of the Creative Commons Attribution 4.0
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monstrated for various MLC designs, showing that leaf
positioning errors need to be considered particularly
when the leaves are moving at maximum speed and/or
for highly modulated MLC patterns [8–11]. Further-
more, Low [8] and Vorwerk [12] proved the dependency
of treatment time on leaf speed limitation. Thereby, not
only the positioning accuracy, but also the velocity of
the leaves is important for high quality plan delivery.
Concerning MLC interdigitation, literature reveals
contradictory findings. Webb [13] describes this feature
as favorable and Tacke et al. [14] show faster delivery
times for complex step-and-shoot IMRT treatment plans
(head-and neck, prostate including lymph nodes). For
VMAT treatments, Van Kesteren et al. [15] show no im-
provement for prostate and rectum treatment plans
whereas Lafond et al. [16] report at least improvements
in delivery efficiency.
While Varian (Varian Medical Systems, Palo Alto, CA,
USA) was the first company to introduce a MLC with a
leaf width of 5 mm for large fields (40 × 40 cm2)– at
least for the inner 20 cm –, Siemens (Siemens Medical
Solutions, Germany) was then the first to provide a MLC
with 5 mm leaf width over the whole 40 × 40 cm2 field
[14]. Besides the Beam Modulator™ MLC (4 mm leaves
over a maximal field size of 21 × 16 cm2) and the MLCi2
(10 mm leaves over the whole field size of 40 × 40 cm2),
Elekta (Elekta AB, Stockholm, Sweden) also introduced
a MLC with 5 mm leaves over a 40 × 40 cm2 field size
(Agility™-MLC). Compared to the Beam-Modulator-
MLC and the MLCi2, the Agility-MLC has lower trans-
mission, as well as improved tongue-and-grove-effect
and penumbra [17].
Numerous studies exist that evaluate the impact of
some specific MLC design parameters on specific delivery
techniques or the impact of different delivery techniques
on certain treatment sites based on miscellaneous physical
and clinical parameters of the dose distribution. As the
various studies used diverse treatment planning ap-
proaches, optimization and dose calculation algorithms,
the relationship of MLC design, delivery technique,
optimization approach and treatment site is hard to ob-
tain. To facilitate conclusions about the influence of differ-
ent MLC design parameters with regard to different
IMRT techniques for complex treatment volumes, this
work presents a consistent planning study comparing
three different MLC designs used with three different
IMRT techniques for two treatment sites, by using a single
treatment planning system.
The influence on clinical relevant parameters (target
coverage, dose to critical structures, monitor units per
plan and treatment times) is shown for different MLC
designs by means of the Elekta MLCi2-MLC (without
(−) and with (+) interdigitation) and the Elekta Agility-MLC and for different IMRT techniques by means of
step-and-shoot IMRT (ssIMRT), dynamic-sliding window
IMRT (dMLC) and volumetric modulated arc therapy
(VMAT). For this comparison, plans were generated
for meningioma and head-and-neck cases, using the
treatment planning software Hyperion V2.4 (University
of Tübingen, Germany, research version of Elekta
MONACO 3.2) that employs constrained optimization
and a Monte Carlo dose algorithm.
Material and methods
A planning study was performed for five head-and-neck
(HN) and five meningioma (MG) cases. For each case,
nine plans were generated: three step-and-shoot IMRT
(ssIMRT), three dynamic-sliding-window-IMRT (dMLC)
and three volumetric modulated arc therapy (VMAT)
plans, with each technique using the MLCi2-MLC with
and without interdigitation (MLCi2+, MLCi2−) and the
Agility-MLC. All plans were generated for an Elekta
6MV linac.
Treatment planning system
Hyperion V2.4 (University Tübingen, Germany, research
version of Elekta MONACO 3.2) was used as treatment
planning system [18–20]. It uses constrained optimization,
i.e. at all stages of optimization all dose-limiting constraints
are ensured to be strictly fulfilled. Hence, in constrained
optimization, PTV coverage is an objective that will be ful-
filled only, if the dose-limiting constraints allow for that.
The functions applied in the optimization may not only be
physical constraints (e.g. dose-volume-constraints, quad-
ratic overdose, etc.) but also functions modelling the bio-
logical effect of radiation to different tissues (e.g. serial or
parallel equivalent uniform dose, EUD) as described by
Alber et al. [21, 22] The optimization is implemented as a
two-step approach: First, the fluence matrix is optimized
using an advanced pencil beam algorithm [23, 24]. Second,
the fluence matrix is segmented into an initial-guess MLC-
sequence and subsequently optimized employing a seg-
ment shape and weight optimization [25]. Final dose calcu-
lation is performed with the XVMC Monte-Carlo dose
engine [26].
VMAT optimization includes the use of the recently
introduced advanced segment shape optimization, as
part of the second stage optimization algorithm. During
the first optimization stage, VMAT fluences are obtained
on equidistant, user-defined gantry angles (15 during
this study). Sequencing translates the fluence maps to
deliverable segments at all available angles as sets of
control points with definition of gantry angle, dose as
MU for the segment and position for every leaf and jaw.
Due to the rotation around the patient, differences in
the OAR-to-PTV projection occur between the 15 equi-
distant gantry sampling points used during the fluence
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after the sequencing step. These are accounted for by
the advanced segment shape optimization by checking
every MLC position for each segment with regard to its
influence on the OAR constraints and the PTV objec-
tives. Thereby each leaf is opened or closed iteratively to
find its optimal position.
MLC properties
The main properties of a MLC are the leaf width, max-
imum speed and minimal gap between opposing leaves
as well as interdigitation capabilities. Table 1 shows all
relevant differences between the MLCi2-MLC and the
Agility-MLC. Generally, the smaller the leaf width, the
better the field shape can be conformed with respect to
the PTV and OARs. This potentially results in better
OAR-sparing while the PTV coverage is maintained. A
minimal leaf gap between two opposing leaves needs to
be maintained for dynamic techniques to prevent collid-
ing leaves. On the other hand, radiation passes through
this gap and causes unwanted dose to tissue and reduces
thereby some degree of freedom in the optimization
process. Therefore, a small leaf gap with low radiation
passing through is wanted. Another possibility would be
backup jaws behind the leaves, under which leaf gaps
could be parked. This could, however, introduce longer
leaf travel paths and thereby increase treatment times
and additionally require interdigitation capabilities. Fur-
thermore, the capabilities of the backup jaw to reduce
inter-leaf transmission vanishes for dynamic techniques
like dMLC and VMAT as the backup jaws can only keep
up with the most retracted leaf. Hence, leaves with a lar-
ger height can reduce the total transmission radiation.
Concerning interdigitation, MLCs with such capabilities
basically allow for independent placement of leaf posi-
tions for all leaf pairs. Generally, this facilitates more
complex segment shapes as well as a larger search space
of segment shapes for the sequencing algorithm to find
an optimal plan. As example, interdigitation offers the
possibility to treat multiple small field openings together
within one segment, which may help to reduce the num-
ber of segments for a given degree of modulation of a
treatment plan as compared to a non-interdigitating
MLC. This potentially reduces the treatment time andTable 1 MLC parameters for MLCi2 and Agility-MLC
MLC parameter MLCi2 Agility
Leaf width 10 mm 5 mm
Leaf speed 20 mm/s 65 mm/s
incl. leaf guide
Min. leaf gap 5 mm 3 mm
Interdigitation −/+ +
Backup jaws yes noMU, especially for larger and complex PTVs. The max-
imum speed of the leaves contributes to several proper-
ties. If the range of available speed is larger, faster plan
delivery with a higher modulation degree is possible; also
potentially reducing MU and scatter radiation.
Thus, different parameters of the MLC can increase or
reduce the degrees of freedom for the optimizer and de-
liverability to a different amount. The MLCi2 −/+ inter-
digitation and the Agility-MLC show differences in these
parameters and capabilities (Table 1), and this study
aims to investigate their contribution to different plans
and treatment sites, which might be different and not
easily foreseen a priori.
Patients
Head and neck cases (HN), being considered challenging
cases of current clinical practice [5], [27], and menin-
gioma (MG) are chosen for the evaluation of the impact
of MLC design and IMRT technique to the plan quality
and potential benefits for the patient due to scatter radi-
ation (MU) and treatment times. Each group includes
five cases of previously treated patients. For HN, target
volume delineation and dose prescription are according
to the ACCRA study [28] requirements with two or
three dose levels (61.6/50.4 Gy or 61.6/56/50.4 Gy), pre-
scribed as SIB-technique in 28 fractions. MG were
treated with 54 Gy in 30 fractions. The MG PTV in-
cludes the GTV based on MR and PET imaging with a
margin of not more than 5 mm. Additional PRV-
margins (3 to 5 mm) to critical structures (e.g. optical
nerves) were applied to improve OAR sparing. Complete
characteristics of the included datasets are shown in
Tables 2 and 3.
Optimization parameters
To access differences due to the IMRT-technique and the
used MLC, all generated plans of the respective case are op-
timized applying the same patient-individual optimization
parameters, i.e. same constrained optimization func-
tions for OAR and PTV objectives with the related param-
eters, same gantry and collimator angles for ssIMRT and
dMLC, as well as same Monte Carlo parameters (beam
model of the radiation sources). Previous studies [29]
show that VMAT plans generated using the Agility-MLC
are superior in terms of higher PTV coverage and homo-
geneity without higher doses to organs at risk (OAR).
Therefore, the applied optimization parameters are ob-
tained from the VMATAgility plan separately for each case.
To emphasize differences in the delivery of the techniques
and the MLC properties, the applied constraints in this
study are not those that were chosen for the clinical treat-
ment plan generation. Instead, dose-limiting constraints
are determined individually on a case-specific basis as low
as realizable such that the PTV coverage is just not
Table 2 Patient characteristics
Meningioma Location PTV volume [cm3]
WHO I
MG1 os sphenoidale right 42
M2G frontobasal right, intra-/supra-sellar 107
MG3 orbital/parasellar right, frontal 173
MG4 temporal right 207
MG5 parasellar 80
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full 360° arcs. These constraints are then used for all other
plans of the respective case. Gantry angles for ssIMRT and
dMLC are obtained from the ssIMRTMLCi2- plan on the
basis of the clinically used gantry angles.
Using constraint optimization, OARs will end up ful-
filling the dose-limiting constraints (mainly) to the same
extent and differences between the plans will be shown
in terms of PTV coverage.
Plan evaluation
Plans are evaluated using dose-volume-histogram (DVH)
analysis and clinically important plan parameters. OAR
exposure is evaluated based on QUANTEC criteria. For
HN, Dmax (dose to 1 % of the volume) for spinal cord,
brain stem, plexus (brachialis ipsilateral, contralateral)
and mandibula, Dmean and V30Gy of the contralateral
parotid gland as well as Dmean and V50Gy of the larynx
are evaluated. For MG, OARs are evaluated by means of
Dmax (dose to 1 % of the volume) for brainstem, chiasm,
optic nerves, eyes, lenses and brain. Additionally, mean
doses for the eyes and V12Gy of the brain are evaluated.
PTV coverage analysis uses an equivalent uniform
dose- (EUD-) definition based on the Poisson model
[18], Dmean, homogeneity (according to ICRU 83, for-
mula 1), and conformity (suggested by Paddick [30],
formula 2).
HIICRU ¼ D2 %−D98 %D50 %
ð1Þ
The homogeneity index (HI) will tend to zero, the bet-
ter the homogeneity of the plan is.Table 3 Patient characteristics
HNSCC
Oropharynx stage location
HN1 pT1 pN2b M0 L0 V0 right
HN2 pT2 pN2b M0 L1 V1 left
HN3 pT3 pN2b M0 L1 V1 right
HN4 pT2 pN2b M0 L0 V0 right
HN5 pT3 pN0 M0 L0 V0 leftThe conformity index (CI) accounts for prescribed
dose outside the PTV and underdosage of the PTV, such
that it equals 1, only if the prescription isodose is sur-
rounding the PTV completely without extending into
normal tissue. Otherwise CI is smaller. The CI is calcu-




VPTV  VD bodyð Þ¼x%
  ð2Þ
Number of segments per plan, MU (as equivalent to
the modulation degree) and estimated treatment times
are compared as clinically important parameters.
As the PTV for each patient has quite a wide range in
volume, location and proximity to OARs, the evaluation
is done patient-wise. The following comparisons are
made:
α) To have a general overview, each plan is compared
to VMATAgility.
β) In order to distinguish differences caused by the
treatment technique independently of which MLC
was used, each technique was compared to the cor-
responding VMAT plan using the same MLC.
Therefore three underlying comparisons were
made, which evaluate the influence of using sIMRT,
dMLC or VMAT together with MLCi2−, MLCi2+
and Agility. In the results Tables 4 and 5, compari-
son of sIMRT and dMLC to VMAT using the
MLCi2- would correspond to comparing column
A/D vs. G (βMLCi2-), while comparing sIMRT and
dMLC to VMAT using MLCi2+ and Agility corre-
sponds to B/E vs. H (βMLCi2+) and C/F vs. I (βAgility),
respectively.PTV volume [cm3]






Table 4 Results for nine plan groups (3 techniques + 3 MLC) for the evaluated parameters for the head-and-neck cases (average and standard deviation for five patients):
QUANTEC criteria where applicable
Head and neck Criteria Step–and–shoot IMRT dmlc IMRT VMAT
MLCi2− MLCi2+ Agility MLCi2− MLCi2+ Agility MLCi2− MLCi2+ Agility
Segmentsa – 97.6 ± 18.3 + 85.8 ± 14.0 + 78.2 ± 11.7 16930 ± 2.6 = 16935 ± 2.7 = 171.2 ± 1.1 338.0 ± 56.7 = 353.8 ± 76.6 = 375.0 ± 57.5 1




– 607.4 ± 92.0 + 571.1 ± 71.2 + 447.2 ± 55.7 + 421.2 ± 30.7 + 420.3 ± 25.0 + 323.2 ± 31.4 + 368.3 ± 28.6 + 361.7 ± 44.7 + 224.4 ± 23.1 3
PTV50 4Gy EUD 50.4 ⇑ 47.7 ± 0.2 < 47.7 ± 0.3 < 47.9 ± 0.5 < 48.8 ± 0.6 < 49.1 ± 0.6 < 49.0 ± 0.4 < 49.5 ± 0.8 < 49.5 ± 0.7 < 50.1 ± 0.5 4
Dmean ⇑ 52.0 ± 1.6 < 52.1 ± 1.5 < 52.1 ± 1.5 < 52.9 ± 1.6 < 52.9 ± 1.6 < 53.0 ± 1.5 < 53.1 ± 1.8 < 53.1 ± 1.7 < 53.3 ± 1.7 5
HIICRU ⇓ 0.436 ± 0.041 + 0.435 ± 0.041 + 0.431 ± 0.037 + 0.408 ± 0.031 + 0.399 ± 0.032 + 0.404 ± 0.036 + 0.380 ± 0.032 + 0.382 ± 0.031 + 0.373 ± 0.032 6
CI100 % ⇑ 0.420 ± 0.098 < 0.433 ± 0.090 < 0.429 ± 0.088 < 0.495 ± 0.075 < 0.507 ± 0.071 < 0.522 ± 0.066 = 0.523 ± 0.106 < 0.521 ± 0.088 < 0.566 ± 0.091 7
CI95 % ⇑ 0.617 ± 0.040 < 0.629 ± 0.038 < 0.634 ± 0.031 < 0.678 ± 0.027 = 0.684 ± 0.028 = 0689 ± 0.026 = 0.692 ± 0.034 < 0.691 ± 0.031 < 0.711 ± 0.033 8
PTV61.6 Gy EUD 61.6 ⇑ 58.4 ± 1.2 < 58.6 ± 1.0 < 58.9 ± 1.3 < 59.9 ± 0.8 < 60.1 ± 0.9 < 60.3 ± 0.9 = 60.3 ± 1.0 < 60.2 ± 1.0 < 60.7 ± 0.9 9
Dmean ⇑ 60.3 ± 0.7 < 60.4 ± 0.7 < 60.5 ± 0.8 < 61.2 ± 0.5 < 61.3 ± 0.6 < 61.4 ± 0.6 = 61.4 ± 0.7 < 61.3 ± 0.7 < 61.6 ± 0.6 10
HIICRU ⇓ 0.175 ± 0.035 + 0.172 ± 0.036 + 0.165 ± 0.040 + 0.140 ± 0.028 + 0.135 ± 0.030 + 0.127 ± 0.033 = 0.128 ± 0.025 + 0.132 ± 0.028 + 0.120 ± 0.027 11
CI100 % ⇑ 0.322 ± 0.084 < 0.326 ± 0.098 < 0351 ± 0.136 < 0.476 ± 0.113 < 0.501 ± 0.127 < 0.539 ± 0.133 = 0.517 ± 0.149 < 0.502 ± 0.132 < 0580 ± 0.146 12
CI95 % ⇑ 0.702 ± 0.04 < 0.704 ± 0.032 < 0.725 ± 0.048 = 0.775 ± 0.033 = 0.776 ± 0.033 = 0.779 ± 0.032 = 0.782 ± 0.037 = 0.779 ± 0.036 = 0.787 ± 0.037 13
Spinal cord
Dmax
50 35.9 ± 4.5 = 35.4 ± 4.0 = 35.1 ± 3.9 = 36.5 ± 4.9 = 35.5 ± 4.0 = 35.6 ± 4.1 = 36.0 ± 4.1 = 35.7 ± 4.5 = 35.5 ± 3.9 14
Brainstem 52 40.1 ± 2.1 = 39.7 ± 2.1 = 39.8 ± 2.4 = 39.0 ± 2.9 = 39.6 ± 2.4 = 40.5 ± 2.4 = 40.0 ± 3.0 = 39.1 ± 2.8 = 39.7 ± 2.7 15
Plexus
ipsilateral
61.6 ⇓ 58.5 ± 5.0 = 58.6 ± 5.6 = 58.6 ± 5.6 = 59.0 ± 5.1 = 59.0 ± 5.2 = 59.0 ± 5.1 = 59.0 ± 5.1 = 59.0 ± 5.2 = 58.9 ± 5.1 16
Plexus
contralateral
50.4 ⇓ 51.3 ± 1.1 = 51.0 ± 0.7 = 50.8 ± 1.4 = 50.9 ± 0.5 = 51.1 ± 0.5 = 51.2 ± 0.7 = 51.5 ± 1.0 = 51.5 ± 0.9 = 51.3 ± 0.8 17
Mandibula 61.6 ⇓ 60.3 ± 3.5 = 60.5 ± 3.6 = 60.4 ± 2.6 = 60.8 ± 2.3 = 60.1 ± 1.9 = 61.1 ± 1.9 = 61.4 ± 2.3 = 61.1 ± 2.7 = 61.6 ± 2.4 18
Parotid
contralateral
Dmean 26 23.9 ± 1.7 < 23.6 ± 2.3 < 23.8 ± 0.8 < 25.3 ± 2.2 = 25.6 ± 1.7 = 25.1 ± 1.6 = 24.8 ± 1.9 = 24.8 ± 1.8 = 25.1 ± 1.7 19
V30 Gy 50 34.2 ± 6.3 = 33.6 ± 7.4 = 33.9 ± 4.5 = 36.3 ± 6.4 = 37.9 ± 5.8 + 36.7 ± 5.4 + 33.8 ± 6.8 = 34.3 ± 6.0 = 34.9 ± 6.0 20
Larynx Dmean ⇓ 46.7 ± 1.2 < 46.3 ± 1.5 < 47.2 ± 1.0 = 47.2 ± 1.1 = 47.3 ± 0.9 = 47.7 ± 0.9 = 47.4 ± 1.8 = 47.2 ± 1.6 = 47.8 ± 1.5 21
V50 Gy ⇓ 14.0 ± 12.3 = 13.9 ± 12.2 = 14.9 ± 15.2 = 16.7 ± 13.5 = 17.7 ± 14.4 = 19.3 ± 14.6 = 18.4 ± 15.4 = 17.5 ± 18.0 = 21.0 ± 18.9 22
A B C D E F G H I
Arrows indicate if a higher or a lower value gives the better plan. “<”,”+” or “=” indicate whether the result is lower, higher or equal to the VMATAgilty according to comparison α (bold) result on a significance level of











Table 5 Results for nine plan groups (3 techniques + 3 MLC) for the evaluated parameters for the meningioma cases (average and standard deviation for five patients):
QUANTEC criteria where applicable
Meningioma Criteria Step–and–shoot IMRT dmlc IMRT VMAT
MLCi2− MLCi2+ Agility MLCi2− MLCi2+ Agility MLCi2− MLCi2+ Agility
Segmentsa – 35.8 ± 10.9 = 36.6 ± 11.5 = 33.8 ± 11.3 158.8 ± 27.5 = 159.4 ± 28.9 = 158.4 ± 24.9 250.4 ± 26.2 = 259.8 ± 25.3 = 26638 ± 28.1 1
MU – 480.8 ± 140.9 = 474.4 ± 128.8 < 452.7 ± 124.9 < 577.9 ± 166.3 = 609.3 ± 194.4 = 612.5 ± 175.5 = 625.4 ± 125.4 = 642.0 ± 143.5 = 569.0 ± 95.5 2
Estimated delivery
time [s]
– 290. ± 90.8 + 297.5 ± 92.3 + 242.1 ± 69.9 + 300.9 ± 91.7 + 299.5 ± 101.9 + 252.4 ± 90.5 + 209.4 ± 24.1 + 209.0 ± 26.7 + 132.3 ± 9.1 3
PTV EUD 54 ⇑ 50.8 ± 2.3 < 51.1 ± 1.9 < 50.9 ± 2.2 < 53.2 ± 0.2 < 53.2 ± 0.3 < 53.5 ± 0.3 < 53.3 ± 0.6 < 53.5 ± 0.1 < 53.8 ± 0.2 4
Dmean 54⇑ 52.6 ± 0.6 < 52.9 ± 0.5 < 52.9 ± 0.5 < 53.9 ± 0.2 < 53.9 ± 0.2 < 54.2 ± 0.2 < 54.0 ± 0.4 < 54.1 ± 0.1 < 54.3 ± 0.2 5
HIICRU ⇓ 0.198 ± 0.072 + 0.187 ± 0.073 + 0.198 ± 0.063 + 0.142 ± 0.043 + 0.139 ± 0.045 + 0.124 ± 0.041 + 0.133 ± 0.045 + 0.125 ± 0.027 + 0.111 ± 0.034 6
CI100 % ⇑ 0.267 ± 0.056 < 0.284 ± 0.056 < 0.323 ± 0.066 < 0.499 ± 0.025 < 0.492 ± 0.027 < 0.590 ± 0.028 < 0.523 ± 0.044 < 0.539 ± 0.045 < 0.638 ± 0.021 7
CI95 % ⇑ 0.622 ± 0.117 < 0.647 ± 0.102 < 0.647 ± 0.107 < 0.750 ± 0.059 = 0.747 ± 0.057 = 0.766 ± 0.062 = 0.760 ± 0.044 = 0.759 ± 0.057 = 0.768 ± 0.055 8
Brainstem
Dmax
54 47.9 ± 10.3 = 48.2 ± 10.4 = 48.2 ± 10.1 = 48.1 ± 10.2 = 48.2 ± 10.3 = 48.3 ± 10.6 = 48.1 ± 10.2 = 48.1 = 10.2 = 48.3 ± 10.1 9
Chiasm 54 53.3 ± 0.7 = 53.5 ± 0.4 = 53.8 ± 0.3 = 53.6 ± 0.4 = 53.7 ± 0.3 = 53.7 ± 0.3 = 53.8 ± 0.3 = 53.8 = 0.2 = 53.8 ± 0.3 10
Opt. nerve left 54 41.7 ± 15.9 = 42.0 ± 16.0 = 42.1 ± 16.0 = 42.1 ± 16.1 = 42.1 ± 16.0 = 42.1 ± 16.1 + 42.1 ± 15.8 = 42.0 = 16.1 = 41.9 ± 16.2 11
Opt. nerve right 54 53.7 ± 0.6 = 53.9 ± 0.2 = 53.8 ± 0.3 = 53.8 ± 0.1 = 53.9 ± 0.1 = 53.8 ± 0.1 = 53.8 ± 0.0 = 53.9 = 0.1 = 53.9 ± 0.1 12
Lens left ⇓ 4.0 ± 1.3 < 4.1 ± 1.2 < 4.1 ± 1.1 < 4.9 ± 1.0 = 4.7 ± 1.3 = 5.0 ± 1.2 = 5.9 ± 0.3 = 6.1 = 0.0 = 6.0 ± 0.1 13
Lens right ⇓ 11.1 ± 9.5 = 11.3 ± 10.0 = 11.1 ± 8.8 = 16.0 ± 10.8 = 14.9 ± 10.3 = 14.4 ± 9.8 = 16.7 ± 11.8 = 16.9 = 11.4 = 16.4 ± 10.2 14
Bulb left Dmean ⇓ 7.9 ± 2.4 = 7.7 ± 2.2 = 7.5 ± 1.7 < 8.4 ± 2.0 = 8.3 ± 2.1 = 8.5 ± 2.2 = 8.9 ± 1.7 = 9.1 = 1.5 = 9.1 ± 1.5 15
Dmax 54 20.0 ± 5.2 = 19.8 ± 5.3 = 20.2 ± 4.5 = 20.5 ± 5.6 = 20.1 ± 4.9 = 21.5 ± 5.6 = 19.3 ± 8.7 = 19.7 ± 8.4 = 20.1 ± 8.0 16
Bulb right Dmean ⇓ 19.0 ± 7.9 = 19.1 ± 8.0 = 20.1 ± 8.4 = 22.5 ± 10.7 = 21.9 ± 10.3 = 22.4 ± 10.9 = 23.0 ± 11.1 = 23.4 ± 11.4 = 23.2 ± 10.9 17
Dmax 54 40.1 ± 13.4 = 39.7 ± 13.3 = 40.5 ± 12.7 = 41.4 ± 13.9 = 41.5 ± 15.0 = 41.3 ± 14.3 = 41.2 ± 13.9 = 41.1 ± 14.6 = 41.0 ± 14.5 18
Brain Dmax 54 53.9 ± 0.8 < 54.1 ± 0.8 < 54.1 ± 0.9 < 54.6 ± 0.6 < 54.5 ± 0.7 < 54.8 ± 0.7 = 54.7 ± 0.8 < 54.8 ± 0.6 < 54.9 ± 0.6 19
V12 Gy ⇓ 43.6 ± 16.4 = 43.7 ± 16.4 = 43.4 ± 15.6 = 43.3 ± 15.7 = 43.6 ± 16.1 = 42.5 ± 16.0 = 43.8 ± 14.8 = 44.6 ± 14.6 = 43.5 ± 13.9 20
A B C D E F G H I
Arrows indicate if a higher or a lower value gives the better plan. “<”,”+” or “=” indicate whether the result is lower, higher or equal to the VMATAgilty according to comparison α (bold) result on a significance level of











Kantz et al. Radiation Oncology  (2015) 10:184 Page 7 of 15γ) In order to distinguish differences caused by MLC in-
dependently of which technique was used, each MLC
was compared to the corresponding Agility plan
using the same technique. Therefore three underlying
comparisons were made, which evaluate the influence
of using MLCi2−, MLCi2+ or Agility together with
sIMRT, dMLC and VMAT. In the results Tables 4
and 5, comparison of MLCi2−/+ to Agility for ssIMRT
would correspond to comparing column A/B vs. C
(γssIMRT), while comparing MLCi2−/+ to Agility for
dMLC or VMAT corresponds to D/E vs. F (γdMLC)
and G/H vs. I (γVMAT), respectively.
For each of the five patients per group, nine plans
combining three different IMRT-techniques (ssIMRT,
dMLC, VMAT) and three different MLCs (MLCi2 −/+
interdigitation, Agility-MLC) are generated. Thereby,
plans are distinguished not only by MLC or technique
but both – MLC and technique.
To conclude the results of the presented study, the mean
and standard deviation for each evaluated parameter over
the 5 patients per group as well as the results of the paired
T-test (significance level: 0.05) for comparisons α, β and γ
are calculated. For a general overview, Tables 4 and 5 show
the results for comparison α (comparison γ for segments).Results
In this study, 10 patients (five HN, five MG) are optimized
for ssIMRT (columns A-C, Tables 4 and 5), dMLC (col-
umns D-F, Tables 4 and 5) and VMAT (columns G-I, Ta-
bles 4 and 5). For each technique, the MLCi2-MLC
without (−) (columns A/D/G, Tables 4 and 5) and with (+)
(columns B/E/H, Tables 4 and 5) interdigitation and the
Agility-MLC (columns C/F/I, Tables 4 and 5) are used.
Thereby, 9 plans per patient are generated. The VMATAgility
plan is considered as a reference for comparisons α, as this
is the plan used to determine all optimization parameters.
An overview of all results of the head-and-neck and men-
ingioma cases is shown in Tables 4 and 5, respectively.
These tables include the results of a paired T-test, but only
for comparison α with the VMATAgility plans. If the plan
compared to is another one, results of the paired T-test are
found in the text. For better understanding, indices from
Tables 4 and 5 are used anyway.
As constrained optimization is used, dose to the OAR dif-
fered only slightly and all QUANTEC criteria are met. If
OAR have to be spared more, the cost would be less PTV
coverage. Among all plans, VMATAgility show best coverage
and fastest delivery. Comparing different techniques (β),
VMAT always shows the fastest delivery. Comparing MLCs
(γ), Agility always shows the fastest delivery. Least MU are
found for ssIMRT plans using the Agility-MLC. The total
amount of MU depends on the PTV size and complexity as
well as on the used technique. The total number ofsegments is independent of the used MLC for MG cases as
well as dMLC and VMAT for HN cases.
Detailed results are as follows:
Head-and-Neck – OAR exposure
As constrained optimization is used, all OARs of
the respective case fulfill the prescribed dose-limiting
constraints. These constraints are optimized case-specific
for this study, based on the VMATAgility plan (I1-I22,
Table 4), and are not the ones clinically chosen,
QUANTEC criteria are met for all OAR except for the
mean dose of the larynx (A-I 21, Table 4).
This is because the PTV50.4Gy surrounds the larynx in all
HN cases, an example case (HN3) is shown in Fig. 1.
Thereby, the QUANTEC criteria of Dmean < 44Gy (A-I 21,
Table 4) is barely achievable, if the PTV is expected to
receive the full dose. Due to the irradiation from all gantry
angles, Dmean (A-I 21, Table 4) and V50Gy (A-I 22, Table 4)
for the larynx are always highest for VMAT, even though
significant differences (p ≤ 0.01) are only found for
ssIMRTMLCi2−/+ (Dmean, A + B 21, Table 4).
For nerve structures (spinal cord – A-I 14, Table 4,
brainstem – A-I 15, Table 4, plexus – A-I 16 + 17, Table 4)
differences in Dmax between techniques and MLCs are not
statistically different from the VMATAgility plan according
to the paired T-test and not larger than 1.5Gy. Within
ssIMRT (γssIMRT, A-C, Table 4), Agility plans (C 14–17,
Table 4) have equal or lower Dmax. Also Dmax (mandibula)
(α, A-I 18, Table 4) overall does not deviate more than
1.5Gy, but with lower doses in general for all ssIMRT
plans (ΔDmax > 1.0Gy, A-C 18, Table 4).
The contralateral parotids (A-I 19 + 20, Table 4) have the
lowest Dmean in ssIMRT (ΔDmean > 1.2Gy, p ≤ 0.02, A-C
19, Table 4). Evaluating V30Gy, dMLC
MLCi2+ and dmlcAgility
plans show V30Gy elevated at least by 5 % (E + F 20,
p < 0.01, Table 4). Comparing MLCs within each technique
(γ), significant (p≤ 0.02, Table 4) differences are only found
for the comparison dmlcMLCi2+ vs. dMLCAgility (E 19 + 20
vs. F 19 + 20, Table 4), showing higher Dmean and V30Gy for
dmlcMLCi2+.
Head-and-Neck – PTV coverage
All OAR sparing compared to VMATAgility comes at
the cost of less PTV coverage. For all criteria (EUD,
Dmean, HI, CI100 %, CI95 % / A 4-I 13, Table 4), VMAT
Agility
(I 4–13, Table 4) has the best PTV coverage.
For PTV50.4Gy (A 4-I 8, Table 4), dMLC plans have
at least 1.0Gy (p ≤ 0.01) and 0.4Gy (p ≤ 0.01) less EUD
(D-F 4, Table 4) and Dmean (D-F 5, Table 4), respect-
ively, and ssIMRT plans have at least 2.1Gy (p ≤ 0.01)
and 1.2Gy (p≤0.01) less EUD (A-C 4, Table 4) and
Dmean (A-C 5, Table 4), respectively. For CI95 %(PTV50.4Gy),
Fig. 1 By example of patient case HN3, relevant isodoses for the larynx (50Gy, 58.5Gy) are shown for the nine generated plans using ssIMRT,
dMLC and VMAT with MLCi2 without (−) and with (+) interdigitation and the Agility-MLC
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the VMATAgility plan (D-E 8 vs. I 8, Table 4). Evaluating
the coverage of PTV61.6Gy, the dMLC
Agility plans show
no significant differences in the evaluated parameters
(F 9–13 vs. I 9–13, Table 4). For PTV61.6Gy only
ssIMRTMLCi2-/+ have significant less conformity of the
95 %-isodose (A + B 13 vs. I 13, Table 4).
Comparing different MLCs within the techniques (γ:
A + B vs. C, D + E vs. F, G + H vs. I, Table 4), significant
differences for the PTV coverage in ssIMRT (γssIMRT:
A + B 4–13 vs. C 4–13, Table 4) are found for CI95 %
(PTV50.4Gy) (p ≤ 0.01) (A 8 vs. C 8, Table 4) and
EUD(PTV61.6Gy) (p ≤ 0.01) (A 9 vs. C 9, Table 4). Within
the dMLC plans(γdMLC), MLCi2+ shows significant
differences only for PTV61.6Gy (Dmean, HI and CI100 %,
E 10–12 vs. F 10–12, Table 4), while MLCi2- has less PTV
coverage (p = 0.01) in terms of Dmean (-1.2Gy) and CI100 %
(-5 %) for PTV50.4Gy and in terms of EUD (-0.4Gy), Dmean
(-0.2Gy), HI (-10 %) and CI100 % (-12 %) for PTV61.6Gy (D
4–13 vs. F 4–13, Table 4).
Comparing different techniques using the same MLC
(ß: A + D vs. G, B + E vs. H, C + F vs. I, Table 4),
ssIMRT plans have worse PTV coverage (p ≤ 0.01) using
either of the three MLCs. Using MLCi2- (ßMLCi2-), dMLC
plans show less homogeneity (p ≤ 0.02) for PTV50.4Gy and
PTV61.6Gy and less EUD (-0.4Gy) for PTV61.6Gy
compared to VMATMLCi2-. For dMLCMLCi2+ (ßMLCi2+),
significant (p ≤ 0.01) differences for the PTV coverage
compared to VMATMLCi2+ are only found for
HI(PTV50.4Gy) (-4 %) (E 4–13 vs. H 4–13, Table 4),
whereas the PTV coverage for dMLC using the Agility-MLC (ßAgility) is less in terms of EUD, Dmean, HI and
CI100 % for both PTVs compared to VMAT
Agility (F 4–13
vs. I 4–13, Table 4).
Figure 2 shows the results for one HN patient (HN3 in
Tables 3) as an example. Figure 2d depicts that the
evaluated OAR parameters differ only slightly between
the techniques and used MLC. As mentioned, larger
differences are found for V50Gy(larynx) (A-I 22,
Table 4), Dmax(mandibula) (A-I 18, Table 4) and the
contralateral parotid (Dmean, V30Gy) (A-I 19 + 20,
Table 4). In contrast to the only slightly differing
clinically important OAR parameters, Fig. 2a, b and c
depict the differences of the PTV coverage: HI, CI and
Dmean drop clearly, if ssIMRT is used. Influences of the
MLC design are only small and highest in combination
with VMAT.
Meningioma – OAR exposure
As for the HN cases, all generated plans fulfill the
prescribed constraints and predefined criteria. Larger
standard deviations for the brainstem (A-I 9, Table 5), left
optical nerve (A-I 11, Table 5), right lens (A-I 14, Table 5)
and bulb (A-I 17 + 18, Table 5) are found due different
proximity of the PTV to these OARs for the different
patients (α).
Differences between the techniques and MLCs are
found for the eyes (A-I 13–18, Table 5). Among all
plans (α), ssIMRT plans preserve lenses and bulbs best
(ΔDmean(bulbs) ≤ 4.2Gy, p ≥ 0.05 (A-C 15/17, Table 5),
ΔDmax(lenses) ≤ 5.3Gy, p ≤ 0.02 (A-C 13 + 14, Table 5)),
a DVH: PTV61.6Gy and PTV50.4Gy
PTV50.4Gy
PTV61.6Gy




































































Fig. 2 Example of one head-and-neck case (HN3). a DVHs for PTV61.6Gy and PTV50.4Gy of all nine generated plans, (b) homogeneity and conformity
indices for PTV61.6Gy and c) PTV50.4Gy, d) evaluated QUANTEC and clinical criteria for OARs
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2.0Gy, p ≥ 0.07 (D-F 13 + 14, Table 5)) and the bulbs
(ΔDmean = 0.6 - 1.4Gy, p ≥ 0.06 (D-F 15/17, Table 5)) bet-
ter than VMAT. Reasons are (1) the use of the advanced
segment shape optimization algorithm for VMAT during
the second optimization step that enables to fully take
advantage of the constraints by placing the leaves more
effectively with respect to PTV coverage and therefore
nearer to the OAR, and (2) VMAT uses the full range of
possible gantry angles, while the gantry angles for ssIMRT
and dMLC were chosen, such that they would avoid
radiation to the eyes more effectively. The use of Agil-
ity shows an influence when using dMLC (γdMLC, F vs.
D+ E, Table 5), presumably due to its interdigitation cap-
abilities and smaller leaves. Overall, only the differences
for the left lens for the ssIMRT plans are significant when
comparing to VMATAgility.Furthermore, significantly (p ≤ 0.01) lower Dmax
(upto 1Gy) are found for brain (A-I 20, Table 5). Only
for dMLCAgility and VMATMLCi2-, these changes are
significant (p ≤ 0.05). The maximal dose of the brain lies
within the PTV. As the PTV coverage is best for
VMATAgility (see next paragraph), higher Dmax(brain) of
these plans can be explained by this.
Meningioma – PTV coverage
As for the HN cases, PTV coverage for the meningioma
cases is best for VMATAgility (A-I 4–8, Table 5). EUD,
Dmean, HI and CI100 % show less PTV coverage for all
other plans. Differences for CI95 % are non-significant
for dMLC and VMAT using either MLC (D-I 8, Table 5).
Larger differences for the PTV coverage (ΔEUD ≥ 2.7Gy
(p ≤ 0.02), ΔDmean ≥ 1.4Gy (p ≤ 0.02)) are found for all
Kantz et al. Radiation Oncology  (2015) 10:184 Page 10 of 15ssIMRT plans (A-C 4–8 vs. I 4–8), showing that also for
meningioma, the technique is more essential than the
MLC design. For all ssIMRT, evaluated parameters show
much less PTV coverage than dMLC or VMAT (A-C 4–8
vs. D-I 4–8, Table 5).
Comparing MLCs within the used techniques (γ: A + B
vs. C, D + E vs. F, G +H vs. I, Table 5), the Agility-MLC
shows significantly higher PTV coverage for the conform-
ity (p ≤ 0.02) of ssIMRT (γssIMRT), but also for EUD, Dmean,
HI und CI100 % within dMLC (γ
dMLC) or VMAT plans
(γVMAT) (p ≤ 0.01 (dMLC), p = 0.02 (VMAT)). Therefore,
the use of the Agility-MLC has more impact for dMLC
and VMAT.
Comparing different techniques using the same MLC
(ß: A + D vs. G, B + E vs. H, C + F vs. I, Table 5),
MLCi2- has (p ≤ 0.01) less PTV coverage for ssIMRT
(ßMLCi2-). Using the MLCi2 with interdigitation,
differences within dMLC plans become significant
(p ≤ 0.02) for EUD, Dmean and CI100 % (ß
MLCi2+).
Even though not significant (p ≥ 0.07), dMLCAgility show
better homogeneity and conformity than any VMATMLCi2
(F 6–8 vs. H 6–8, Table 5), showing that (1) the used
gantry angles are chosen such, that comparable plans
to VMATAgility are possible and (2) smaller leaves are
favorable when small OAR within the PTV need to be
preserved. Still the PTV coverage in terms of EUD and
Dmean for dMLC (all MLCs) are within the range of the
VMAT plans (ΔEUD= 0.2 - 0.6Gy (D-F 4 vs. G-I 4,
Table 5), ΔDmean = 0.2 - 0.4Gy (D-F 5 vs. G-I 5, Table 5)).
For all ssIMRT, evaluated parameters show much less
PTV coverage than dMLC or VMAT (A-C 4–8 vs. D-I
4–8, Table 5).
Figure 3 shows the results for one meningioma patient
(MG2 in Tables 2) as an example. Firgure 3c depicts that
the evaluated OAR parameter differ only for the bulbs
(Dmean, Dmax) and the lenses (Dmax). In contrast, Fig. 3a
and b depict the differences of the PTV coverage:
homogeneity, conformity and Dmean drop clearly, if
ssIMRT is used. Influences of the MLC design are only
small and highest in combination with VMAT.
Estimated treatment times
The reported treatment times are not measured, but
estimated from the TPS with realistic assumptions for
the dose rate, leaf and gantry rotation velocity. Hence,
times within this study are at least comparable among
each other. As absolute times depend on the maximal
achievable dose rate, leaf and gantry rotation velocity of
a specific linac, the actual delivery times may deviate
about few percent from those treatment times estimates.
However, differences between techniques or MLCs from
the presented study may be compared to other studies in
a relative manner.The analysis of the estimated treatment time shows, that
the combination of VMAT and Agility results in the
fastest treatment for each case. This is still true when
using up to three arcs for HN cases and the time
difference can be up to 481 s (≈8 min) for single cases
(HN2), comparing VMATAgility vs. ssIMRTMLCi2-.
Comparing each technique using either MLC (ß: A +D 3
vs. G 3, B + E 3 vs. H 3, C + F 3 vs. I 3, Tables 4 and 5),
fastest (p ≤ 0.01) treatment plans are found among VMAT,
regardless of the PTV complexity (shape, dose levels,
proximity to OARs), while ssIMRT takes the most time
(A-C 3 vs. D-F 3 vs. G-I 3, Tables 4 and 5). The MLC in-
fluences the amount of time that can be reduced by chan-
ging from one technique to another. VMATMLCi2-/+
reduces the treatment time about 60 % compared to
ssIMRT with MLCi2-/+ (ßMLCi2-/+: A + B 3 vs. G+H 3,
Tables 4 and 5) and almost 50 % with Agility (ßAgility: C 3
vs. I 3, Tables 4 and 5). For dMLC, treatment times are re-
duced by about 15 % (ßMLCi2-/+: D + E 3 vs. G+H 3,
Tables 4 and 5) and 45 % (ßAgility: F 3 vs. I 3, Tables 4 and
5) using MLCi2-/+ and Agility, respectively.
Comparing the MLCs using either technique (γ), Agility
on average offers faster (p ≤ 0.01) treatments by 48/55 s
for ssIMRT (γssIMRT: A + B 3 vs. C 3, Table 5), 48/47 s for
dMLC (γdMLC: D + E 3 vs. F 3, Table 5) and 77/76 s for
VMAT (γVMAT: G +H 3 vs. I 3, Table 5) for meningioma
using the MLCi2-/+. This corresponds to about 20 %
longer treatments for ssIMRT and dMLC and 58 %
longer treatments for VMAT with MLCi2. For the larger
and more complex PTVs of the HN cases, Agility is
faster by 160/124 s for ssIMRT(γssIMRT: A + B 3 vs. C 3,
Table 4), 98/97 s for dMLC (γdMLC: D + E 3 vs. F 3,
Table 4) and 143/137 s for VMAT (γVMAT: G +H 3 vs.
I 3, Table 4) for MLCi2- and MLCi2+, respectively,
corresponding to 28 and 36 % longer treatments for
ssIMRT, 30 % longer treatments for dMLC and over
60 % longer treatments for VMAT when using the
MLCi2.
The ability of interdigitation of the MLCi2 does not
reduce treatment times much. Larger time reduction is
found for ssIMRT, only (HN: 36 s, 10 %, p = 0.07, A 3
vs. B 3, Table 4, MG: 7 s, 3 %, p ≤ 0.01, A 3 vs. B 3,
Table 5).
Monitor units
MU for HN and MG are least for ssIMRTMLCi2+ and
ssIMRTAgility (B/C 2, Tables 4 and 5).
Compared to MLCi2- and MLCi2+, Agility saves MU for
HN cases using ssIMRT (32 %, 13 %, p ≤ 0.01 (γssIMRT: A/
B 2 vs. C 2, Table 4)) and VMAT (7 %, 10 %, p ≤ 0.01
(γVMAT: G/H 2 vs. I 2, Table 4)), but not for dMLC (γdMLC:
D/E 2 vs. F 2, Tables 4 and 5) or MG cases (γ: A/B 2 vs.



















b PTV coverage c OAR exposure
Fig. 3 Example of one meningioma case (MG2). a DVH for the PTV of all nine generated plans, (b) homogeneity and conformity indices for the
PTV, c) evaluated QUANTEC and clinical criteria for OARs
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cases (ß), ssIMRT plans have the least MU as compared
to the respective VMAT plans (ΔMU= 23 %/26 %/20 %,
p ≤ 0.01, MLCi2-/MLCi2+/Agility, A/B/C 2 vs. G/H/I 2,
Table 5), while no significant changes (p ≥ 0.36) between
dMLC and VMAT are found. For HN cases VMAT
increases MU compared to dMLC (ΔMU= 19 %/18 %/
10 %, p ≤ 0.01, MLCi2-/MLCi2+/Agility, D/E/F 2 vs. G/H/
I 2, Table 4) and ssIMRT (ΔMU= 9 %/25 %/26 %, p ≤
0.01, MLCi2-/MLCi2+/Agility, A/B/C 2 vs. G/H/I 2,
Table 4). Interdigitation reduces the MU for HN cases
for ssIMRT by 15 % (p ≤ 0.01) (A 2 vs. B 2, Table 4).
This shows that the reduction of MU depends not only
on the size and complexity of the treated volume but
also on the technique and the MLC.
Segments
The number of segments for the different MLCs for a
given treatment technique (γ) is also investigated (A-I 1,
Tables 4 and 5).
For dMLC and VMAT (γdMLC/VMAT), the amount of
segments does not change significantly with the MLC andonly slightly with the plan complexity (mean number of
segments: MG: 159 (dMLC, D-F 1, Table 5)/259 (VMAT,
G-I 1, Table 5), HN: 170 (D-F 1, Table 4)/356 (VMAT,
G-I 1, Table 4)).
For ssIMRT (γssIMRT), segments do not change with the
MLC (34–37 segments, p ≥ 0.15 (A-C 1, Table 5)) for the
MG cases, but for the HN cases (+19/8 segments
MLCi2-/+, p ≤ 0.01,(A-C 1, Table 4)). Interdigitation
reduces the amount of segments by 12 % (p ≤ 0.01) for
HN cases using ssIMRT (A 1 vs. B 1, Table 4).
Discussion
This work evaluates the impact of the MLC design
(MLCi2 without (−) and with (+) interdigitation, and
Agility-MLC) with regard to different IMRT techniques
(ssIMRT, dMLC, VMAT) for head-and-neck and men-
ingioma cases by means of PTV coverage, dose to OARs
and some plan related parameters (MU, segments, treat-
ment time).
One single person generated all plans using the same
TPS version and dose algorithms, in order to keep
the bias of this study low. Inevitably, differences are
introduced by different optimization and sequencing
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results are to some extent specific for the TPS (and its
version) used in this study. By design of this study, the
aim was to create plans where the dose to OARs within
each case is comparable, thereby revealing the specific
impact of MLC design and IMRT technique in terms of
the target coverage. Thus, constrained optimization was
used to find a Pareto optimal plan, which had all dose-
limiting constraints minimized individually on a case-
specific basis, such that the PTV coverage was just not
affected for the VMATAgility plan. As ssIMRT and dMLC
use static gantry angles, the chosen angles may affect the
results. However, as the results show, dMLCAgility plans
degrade only slightly compared to VMATMLCi2−/+, show-
ing that the selected gantry angles were chosen reason-
ably with respect to PTV and OAR and therefore
differences result from the used IMRT technique and
MLC design.
As intended by constrained optimization, OAR expos-
ure is within the prescriptions and therefore mainly the
same for all 9 plans of each case (Figs. 2d and 3c). Dose
differences within the prescribed limits are found, be-
cause the used prescription functions (modelling the
biological effect of radiation to different tissues) do not
match the clinical evaluated parameters. As the prescrib-
ing functions consider the organ exposure as a whole in
terms of EUD (applying model specific parameters) and
not in terms of single dose-volume-parameters, DVH
curves may differ but result in the same EUD. Especially
if critical structures are close to the PTV or belong par-
tially to the PTV (larynx, parotid glands, mandibula,
eyes), OAR exposure of a certain part of the DVH rises
slightly with increased PTV coverage for the VMAT
plans. However, as other parts of the same OAR can be
preserved better by more complex techniques, the EUD
remains the same. The higher OAR exposure for certain
DVH parts found for more complex techniques is not
only caused by higher scatter due to employing more
beam directions and MU [31–33], but also due to the re-
cently introduced advanced segment shape optimization
that places leaves in VMAT optimization more effect-
ively, such that constraints are not violated but PTV
coverage is improved. By this, the distance between the
projected leaf tip position and the OAR can be smaller
for VMAT than for ssIMRT and dMLC.
The main results of this study show that (1) the smaller
leaves of the Agility-MLC are capable of sparing the OARs
to the same extent as with the MLCi2+/−, while increasing
the PTV coverage, (2) using Elekta-VMAT planned with
the TPS Hyperion V2.4 (equivalent to using Monaco 3.2)
does not suffer the loss of either OAR sparing or PTV
coverage and (3) Elekta-VMAT using the Agility-MLC
planned with the TPS Hyperion V2.4 offers faster treat-
ments than using the MLCi2+/− or ssIMRT and dMLC.Some authors [1, 5, 6, 15, 16, 33–37] studied the im-
pact of different MLC properties showing 4 or 5 mm leaf
width to be slightly superior over 10 mm leaf width in
terms of either better PTV coverage, homogeneity and
conformity or OAR sparing. Especially small OAR or
target structures with small concavities will profit. As
the aim of the presented study was to isolate differences
in PTV coverage, homogeneity and conformity, narrower
leaves give plans with higher mean dose to the target as
well as improved homogeneity and conformity, for most
cases. Consistent to van Kesteren et al. [15] and Lafond
et al. [16], interdigitation had only little impact on im-
proved PTV coverage, but could improve delivery effi-
ciency by means of reduced MU [16], because in critical
situations, OAR sparing can be performed more pre-
cisely and efficiently, if leaves can move freely. If inter-
digitation of the leaves is possible, the algorithm can
choose the most efficient mode of sparing.
Higher impact on improved PTV coverage is found by
technique. Shown by others [31, 33, 35, 38–42], compar-
able or slightly improved PTV coverage with better con-
formity and homogeneity is found comparing static or
dynamic IMRT techniques to rotational IMRT. The re-
cently introduced advanced segment shape optimization
routine further improves homogeneity, especially for
meningioma cases. Here, leaves are more effectively
placed for better OAR sparing and better PTV coverage.
Consequently, best PTV coverage is obtained for
VMATAgility optimized with the advanced segment
shape optimization routine.1
Forty to 50 % treatment time reduction is reported
using VMAT instead of ssIMRT and MLCi2 for cases
with medium or high PTV complexity (prostate, HN,
lung) [31, 33, 38, 39, 42]. This current study also shows
37 to 50 % faster treatments for highly complex PTVs
(HN) and 28 to 45 % for less complex PTVs (MG) using
VMAT instead of ssIMRT. Wizorek et al. [43] report
over 75 % faster treatments with RapidArc compared to
dynamic IMRT for HN cases, whereas this study finds
13 and 30 % (MLCi2−/+ and Agility) for HN and 30 and
48 % (MLCi2−/+ and Agility) for MG. Reasons for this
discrepancy of time speed up between the according
Varian techniques (dynamic IMRT compared to Rapi-
dArc) on the one hand, and the Elekta techniques
(dMLC compared to VMAT) on the other hand, may be
manifold. First, RapidArc uses a different approach, in
which the gantry speed modulation is considered to a
smaller degree as for VMAT, mainly trying to keep gantry
rotation speed at maximum. Second, this study uses two to
three arcs and nine gantry angles instead of always two arcs
and seven fields as Wizorek et al. Third, constraints are
tighter in this study, resulting in more complex and
therefore longer treatments. Forth, treatment times for
dynamic IMRT in head-and-neck IMRT as reported by
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treatment times calculated for this study using dMLC
(7.0 ± 0.4 min). Therefore, a relatively higher gain in
treatment time is possible. These higher treatment
times for dMLC-IMRT calculated with Eclipse TPS is
also shown by Shang et al. [44] (rectal cancer: 8.0 ±
0.7 min) and Jeong et al. [45] (HN: 11.7 to 19.6 min,
depending on the number of fields).
The Agility-MLC accelerates treatments compared to
MLCi2−/+ in this study by 22–26 % (HN) and 17–19 %
(MG) for ssIMRT und dMLC, presumably due to higher
leaf speed. Only evaluating VMAT, treatments are about
39 % faster for HN and meningioma. Bedford et al. [27]
report 53 % accelerated VMAT treatments for typical
HN. Tighter constraints in the presented study can cause
longer treatment times for all techniques, and Bedford
et al. use only one arc, a maximum delivery time con-
straint as well as a different optimization approach.
Even though reported treatment times are not mea-
sured but TPS-calculated and therefore only estimates,
calculations were done with realistic assumptions for the
dose rate, leaf and gantry rotation velocity. All these pa-
rameters were the same throughout the study. The abso-
lute treatment times depend on the maximal achievable
dose rate, leaf and gantry rotation velocity of a specific
linac and may vary due to daily output variations, the ac-
tual wear of the single moving components as well as
MLC calibration and beam tune. Hence, treatment times
are comparable within this study and at least comparable
in a relative manner to other studies.
A decrease in MU when treating HN with VMAT
(1–2 arcs) instead of ssIMRT of 9 to 20 % has been re-
ported [31, 33, 42]. Contrary, we find increased MU
(10 % MLCi2− (p = 0.06), 25 % MLCi2+ (p ≤ 0.01), 26 %
Agility (p ≤ 0.01)) as also found by Guckenberger et al.
[31] (7 % MLCi2−) when using three arcs for VMAT.
Large MU reductions (35–60 %) compared to dMLC are
reported for RapidArc [40, 43–47]. In the presented
study, again, increased MU (10–19 %) are found if using
VMAT instead of dMLC for HN cases. For MG, no sig-
nificant MU reduction between dMLC and VMAT is
found. One reason is that dMLC, calculated with Eclipse
for Varian linacs, typically produces over 1100MU as
compared to 800MU in this study, while for RapidArc
less MU than for Elekta-VMAT are needed [40].
Burmeister et al. [1] found increased MU for narrower
leaves while Wang et al. [36] report less MU for narrower
leaves (4 mm). Also the presented data show improved
MU efficiency with the narrower leaf MLC (Agility) for
ssIMRT and VMAT. One reason could be that Burmeister
normalized the plans. As in that study, homogeneity and
Dmin of the PTV was less for the narrower leaf plans, the
normalization can involuntarily cause higher mean dose
in the PTV and thereby higher MU. Besides, lowertransmission leads to lower doses (esp. low dose region) in
OARs [5] possibly enabling the constrained optimization
algorithm to achieve higher PTV coverage for a given
amount of extra dose due to MLC transmission. There-
fore, presumably the lower transmission of the Agility-
MLC compared to the MLCi2 is also one reason for im-
proved MU efficiency.
Conclusion
Best plans in terms of PTV coverage (EUD, Dmean, HI,
CI) while maintaining the OAR exposure and treatment
delivery time are found for VMAT plans, delivered with
the Agility-MLC. Due to reduction in transmission and
improvements in leaf speed, these plans have only 3 and
16 % (HnN/meningioma) more MU than the corre-
sponding ssIMRT, delivered with a non-interdigitating
MLCi2.
Endnotes
1This advanced segment shape optimization routine is
also available for ssIMRT in Monaco 5.1 and higher, and
for dMLC in Monaco 5.0 and higher. With this, im-
proved plans for ssIMRT and dMLC will be found.
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